Delving into the Latest Updates on Carteolol Hydrochloride/Latanoprost with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Carteolol/latanoprost, Mikeluna

+ [1]

Target

PTGFR x β1-adrenergic receptor x β2-adrenergic receptor

Mechanism

PTGFR agonists(Prostanoid FP receptor agonists), β1-adrenergic receptor agonists(Beta-1 adrenergic receptor agonists), β2-adrenergic receptor antagonists(Beta-2 adrenergic receptor antagonists)

Therapeutic Areas

Eye Diseases

Active Indication

GlaucomaOcular HypertensionGlaucoma, Open-Angle

Inactive Indication-

Originator Organization

Otsuka Pharmaceutical Co., Ltd.

Active Organization

Otsuka Holdings Co., Ltd.

Otsuka Pharmaceutical Co., Ltd.

Teika Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (28 Sep 2016),

GlaucomaOcular Hypertension

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC26H40O5

InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N

CAS Registry130209-82-4

View All Structures (2)

Primary objective To evaluate the superiority of OPC-1085EL eye drops in lowering intraocular pressure compared with 0.005% latanoprost eye drops in Chinese subjects with primary open-angle glaucoma or ocular hypertension. Secondary objective To compare the safety of OPC-1085EL eye drops and 0.005% latanoprost eye drops.

Start Date27 Sep 2022

Sponsor / Collaborator

Teika Pharmaceutical Co., Ltd.

[+2]

NCT05583474

/ RecruitingPhase 3

A Phase III, Multi-center, Randomized, Single-blind (to Evaluator), Parallel, and Positive-controlled Clinical Trial Evaluating the Efficacy and Safety of OPC-1085EL Ophthalmic Solution in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular hypertension in Chinese subjects. It is planned that 240 subjects (120 in each group) will be randomly assigned to receive OPC-1085EL or 0.005% latanoprost ophthalmic solution (latanoprost) at a ratio of 1:1.

Start Date27 Sep 2022

Sponsor / Collaborator

Otsuka Beijing Research Institute

JPRN-UMIN000030288

/ CompletedNot ApplicableIIT

Investigation on the Efficacy and Safety of Carteolol/Latanoprost Combination Ophthalmic Solution to Timolol/Latanoprost Combination Ophthalmic Solution in Patients with Glaucoma - Investigation on the Efficacy and Safety of Carteolol/Latanoprost Combination Ophthalmic Solution in Patients with Glaucoma

Start Date22 Nov 2017

Sponsor / Collaborator-

100 Clinical Results associated with Carteolol Hydrochloride/Latanoprost

Login to view more data

100 Translational Medicine associated with Carteolol Hydrochloride/Latanoprost

Login to view more data

100 Patents (Medical) associated with Carteolol Hydrochloride/Latanoprost

Login to view more data

1

Literatures (Medical) associated with Carteolol Hydrochloride/Latanoprost

01 Nov 2016·American Journal of OphthalmologyQ2 · MEDICINE

Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension

Q2 · MEDICINE

Article

Author: Toru Ikegami ; Tetsuya Yamamoto ; Yuji Ishikawa ; Opc El Study Groups ; Satoru Kikuchi

PURPOSETo assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) vs latanoprost (Study 1) and carteolol (Study 2) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).DESIGNMulticenter, randomized, evaluator-masked (Study 1)/double-masked (Study 2), parallel-group studies.METHODSSetting: Twenty-eight clinical sites (Study 1) and 19 clinical sites (Study 2) in Japan.STUDY POPULATIONOutpatients with bilateral POAG or OH whose predose IOP was 18 to <35 mm Hg in the study eye after 4 weeks' treatment with latanoprost (Study 1) or carteolol (Study 2) (defined as baseline).INTERVENTIONIn Study 1, 237 patients applied OPC-1085EL (n = 118) or latanoprost (n = 119) for 8 weeks. In Study 2, 193 patients applied OPC-1085EL (n = 78), carteolol (n = 78), or carteolol/latanoprost concomitant therapy (n = 37) for 8 weeks.MAIN OUTCOME MEASUREAdjusted mean IOP reduction at predose from baseline to week 8.RESULTSIn Study 1, the adjusted mean IOP reductions (95% confidence interval [CI]) were 2.9 (2.5-3.3) mm Hg and 1.6 (1.2-2.0) mm Hg in the OPC-1085EL and latanoprost groups, respectively (P < .0001). In Study 2, the adjusted mean IOP reductions (95% CI) were 3.5 (3.1-3.9) mm Hg and 1.6 (1.2-2.0) mm Hg in the OPC-1085EL and carteolol groups, respectively (P < .0001). All adverse drug reactions of OPC-1085EL observed in both studies were mild in severity and only 1 patient in each study discontinued because of an adverse drug reaction.CONCLUSIONSOPC-1085EL is superior to latanoprost or carteolol alone in terms of lowering IOP, and was well tolerated.

100 Deals associated with Carteolol Hydrochloride/Latanoprost

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	S01ED55	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	JP	Otsuka Holdings Co., Ltd.	28 Sep 2016
Ocular Hypertension	JP	Otsuka Holdings Co., Ltd.	28 Sep 2016

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Open-Angle	Phase 3	CN	Teika Pharmaceutical Co., Ltd.	27 Sep 2022
Glaucoma, Open-Angle	Phase 3	CN	Otsuka Pharmaceutical Co., Ltd.	27 Sep 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2019	Not Applicable	Glaucoma	152	Xalacom	(xpviurirge) = nfeseygdqv urrizaopap (swjfoobmxu )	-	01 Jul 2019
				Duo Trav	(xpviurirge) = uanxrazlad urrizaopap (swjfoobmxu )
NCT02105285 (CTgov)	Phase 3	Glaucoma	193	OPC-1085EL ophthalmic solution (OPC-1085EL Ophthalmic Solution)	erdvgkwpfv(swnllorkic) = weqyzgzshf cryxrpyuay (qrgctfhwcb, lzfszdwdrx - ixajdmtbne) View more	-	17 Nov 2015
				Carteolol long-acting ophthalmic solution (Carteolol Long-acting Ophthalmic Solution)	erdvgkwpfv(swnllorkic) = klfagyucni cryxrpyuay (qrgctfhwcb, emsewxnecf - stnrdbuunr) View more
NCT02105272 (CTgov)	Phase 3	Glaucoma	237	OPC-1085EL ophthalmic solution (OPC-1085EL Ophthalmic Solution)	yqwwgqdscr(wyexytdpqc) = ilzhmcdwqe xkwphjemwb (qllivbyvzs, vxvtklmmmy - pckfipztum) View more	-	17 Nov 2015
				Latanoprost ophthalmic solution (Latanoprost Ophthalmic Solution)	yqwwgqdscr(wyexytdpqc) = avjtugaedl xkwphjemwb (qllivbyvzs, rgvpdrzcgt - gxsdagjjom) View more
NCT02108288 (CTgov)	Phase 1	Glaucoma	30	OPC-1085EL ophthalmic solution (OPC-1085EL Ophthalmic Solution)	hvmardjnna(jvwiiksirf) = czgawuhwne yijzwllyxe (mpognzkbqz, cvrvsxemft - uiknnixyrx) View more	-	02 Apr 2015
				Carteolol long-acting ophthalmic solution (Carteolol Long-acting Ophthalmic Solution)	hvmardjnna(jvwiiksirf) = lpsrgeaaaz yijzwllyxe (mpognzkbqz, duecucpodx - rywoivcvyf) View more